The Urgent Need for Measles and Rubella Eradication

By Melike Belenli Gümüş

August 8, 2024

Introduction

Fifty years after the initiation of the Expanded Programme on Immunization in 1974, life-saving vaccines have reformed global healthcare. Among these, the measles-containing vaccine (MCV) stands out for its unparalleled role in reducing child mortality rates, preventing an estimated 57 million deaths worldwide between 2000 and 2022. Despite significant progress, diseases such as measles and rubella continue to pose a threat, particularly in developing countries. The COVID-19 pandemic has further complicated efforts, highlighting the need for renewed focus and coordinated action. In their recent article, Durrheim et al. indicated the current state of measles and rubella worldwide, the challenges faced, and the strategies required to achieve measles and rubella eradication.

The Current State of Measles and Rubella Vaccination

Measles and rubella remain significant public health concerns. In 2021, only 81% of children received their first dose of the measles-containing vaccine (MCV1), the lowest coverage since 2008. This left 25 million children vulnerable to measles. By 2022, MCV1 coverage had increased slightly to 83%, but this was still below the pre-pandemic level of 86%. The result has been large, disruptive outbreaks in many countries, with a global epidemic curve resembling that of 2018 and early 2019.

Figure 1: Measles reported cases worldwide, 1974–2022. Source: World Health Organization. Global Health Observatory.

Measles not only poses immediate threats but also leads to immunosuppression in children, increasing their susceptibility to other infections. This explains a significant portion of childhood deaths post-measles infection. The measles vaccine is highly cost-effective, with data indicating that for every US$ 1 invested in vaccination from 2001 to 2020, US$ 58 were saved in future costs. Modelling shows that measles vaccination can prevent 37% of deaths from 14 key pathogens between 2021 and 2030, saving 18.8 million lives in this decade alone.

Impact of the COVID-19 Pandemic

The COVID-19 pandemic has had a profound impact on measles and rubella eradication efforts. The pandemic led to the closure of country borders, a dramatic decrease in international travel, and the implementation of wide-scale non-pharmaceutical public health measures. These actions significantly obstructed the importation and transmission of measles and rubella viruses. However, the pandemic also disrupted routine immunisation programmes and postponed vaccination campaigns, creating immunity gaps.

The Immunisation Agenda 2030

The Immunisation Agenda 2030 (IA2030) of the World Health Organization (WHO) recognises measles as a tracer of the strength of immunisation programmes. Strategic priority 3 of IA2030 notes that measles cases and outbreaks should identify weaknesses in immunisation programmes and guide programmatic planning. Nevertheless, IA2030 will inevitably fail unless measles and rubella eradication efforts are accelerated. This includes achieving impact goals such as reducing deaths, endorsing elimination targets, and increasing global coverage with the second dose of the measles-containing vaccine (MCV2) to 90%.

The Moral Imperative for Eradication

There is a moral imperative to commit to and achieve measles and rubella eradication. The ongoing disease burden and preventable deaths due to measles are unacceptable. The rule of rescue demands that if we have effective tools, we should make every effort to save lives. The eradication of measles, rubella, and congenital rubella syndrome (CRS) should not remain as a technically possibility but must be achieved to prevent children from facing avoidable childhood mortality and lifelong disabilities. This completion is essential to secure a future where children are not burdened by these preventable health risks.

Conclusion

Measles and rubella eradication represent a moral imperative and a critical public health goal. The global community must act now to close immunity gaps, strengthen immunisation programmes, and commit to the goals of the Immunisation Agenda 2030. By fostering collaboration, securing adequate resources, and engaging diverse stakeholders, we can ensure a future where preventable childhood diseases like measles and rubella are consigned to history. This action will safeguard the health and well-being of generations to come.

Reference url

Recent Posts

digital HIV self-testing
        

Cost-Effectiveness of Digital HIV Self-Testing

💡 Is digital innovation the key to enhancing HIV testing in high-prevalence regions?

A recent study reveals that digital HIV self-testing (HIVST) not only proves cost-effective but significantly improves care linkage, particularly among populations with higher HIV test-positivity rates. This data-driven approach could reshape public health strategies in Malawi, South Africa, and Brazil!

Jump into the findings and implications for policy and health equity in our latest article!

#SyenzaNews #digitalhealth #HealthEconomics #costeffectiveness

gene therapy sickle cell
            

NICE Approves Gene Therapy for Sickle Cell: A Breakthrough in Treatment and Health Equity

🌟 Are we on the brink of a cure for sickle cell disease?

The recent approval of a one-off gene therapy by NICE offers hope for individuals suffering from severe sickle cell disease, addressing both health outcomes and economic disparities. This breakthrough not only promises to enhance quality of life but also tackles the socio-economic challenges associated with the disease.

Jump into the full article to learn more about the implications of this gene therapy and its potential impact on the healthcare landscape.

#SyenzaNews #HealthEconomics #HealthcareInnovation #CostEffectiveness

cervical cancer app
       

Cervical Cancer App: Enhancing Screening and Treatment

✨ *Can a mobile app change the future of cervical cancer screening in Kenya?*
A recent clinico-economic model unveils how a cervical cancer app could significantly enhance screening processes and improve treatment outcomes for women in Kenya. This innovative approach not only increases detection rates but also shows long-term cost savings in managing cervical cancer.

Explore the full article to learn how mobile health technology can tackle this pressing public health challenge!

#SyenzaNews #digitalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.